PIH3 Pregnancy Outcomes Folowing Exposure to Serotonin Reuptake Inhibitors: A Meta-Analysis

Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Reproductive Toxicology (Impact Factor: 2.77). 12/2006; 22(4):571-5. DOI: 10.1016/j.reprotox.2006.03.019
Source: PubMed

ABSTRACT Serotonin reuptake inhibitors (SRIs) are extensively used in management of clinical depression. Reports vary about the risk of these drugs during pregnancy. To determine the risk of exposure to SRIs, we pooled data from multiple clinical studies that investigated obstetrical outcomes in women exposed to this group of drugs during pregnancy. Studies were identified by search of PUBMED, OVID, and SCOPUS databases and the data were derived from 1990 to 2005 (August). Types of outcome investigated were spontaneous abortion, major malformations, cardiovascular malformations, and minor malformations. The criteria for inclusion of studies in this meta-analysis were exposure of women to any therapeutic dosage of SRI (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) during pregnancy. Our results find that SRIs do not increase the risk of major, cardiovascular and minor malformations but do increase the risk of spontaneous abortion significantly.



Available from
Dec 31, 2014